Malin investors urged to reject executive pay deal
Series of investments in life science companies have been badly received by the market
Series of investments in life science companies have been badly received by the market
Melinta Therapeutics is Malin’s second-largest investment by capital committed
Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair
Irish life sciences firm also commits further $10m in company
Britsh fund manager Neil Woodford also purchasing shares
Elan executives turn their sights to funding side of biotech/life sciences business
Former Elan boss Kelly Martin and chairman Bob Ingram to sit on company’s board
Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday
Founded in 1996, it built a major business by procuring the rights to royalties of some of the major drugs in the market, including Humira, Januvia, Lyrica and Remicade
Royalty Pharma last week increased hostile cash bid for Elan
Crosswords & puzzles to keep you challenged and entertained
Full general election coverage including analysis and results for all 43 constituencies
How does a post-Brexit world shape the identity and relationship of these islands
Weddings, Births, Deaths and other family notices